Current evidence on the interplay between mitochondrial dysfunction, telomere dynamics, genetic variation and environmental influences in CKD are synthesized to provide a comprehensive framework for understanding CKD and advancing precision medicine approaches.
Abstract
Chronic kidney disease (CKD) is a major global health burden characterized by progressive loss of renal function and an increased risk of cardiovascular morbidity and mortality. The risk of adverse outcomes rises with declining glomerular filtration rate, with cardiovascular disease representing the leading cause of death in advanced CKD. In addition to traditional risk factors such as diabetes and hypertension, oxidative stress and mitochondrial dysfunction have emerged as key contributors to disease pathogenesis. Oxidative stress in CKD arises from mitochondrial dysfunction and inflammation-mediated pathways, leading to endothelial dysfunction, chronic inflammation and accelerated cellular aging. Coenzyme Q10 (CoQ10), a lipid-soluble component of the mitochondrial electron transport chain, plays a central role in cellular bioenergetics and antioxidant defense. Reduced CoQ10 levels observed in CKD contribute to impaired mitochondrial function and increased oxidative damage. Genetic variation in pathways regulating oxidative stress and CoQ10 metabolism may influence CKD susceptibility. Polymorphisms such as NQO1 rs1800566 affect the reduction of CoQ10 to its active antioxidant form and may modulate individual responses to oxidative stress. Telomere shortening, a marker of biological aging, is closely associated with oxidative stress and has been linked to CKD progression. Recent advances in genomic research have enabled the development of genetic risk scores (GRS) that integrate multiple genetic variants to predict disease susceptibility. In addition, social determinants of health (SDoH), including socioeconomic and environmental factors, significantly influence CKD outcomes through their impact on biological pathways. This review synthesizes current evidence on the interplay between mitochondrial dysfunction, telomere dynamics, genetic variation and environmental influences in CKD. The therapeutic potential of CoQ10 supplementation is also discussed. Integrating molecular, genetic and social determinants provides a comprehensive framework for understanding CKD and advancing precision medicine approaches.
This review emphasizes not only mechanistic advances but also conflicting findings, model limitations, and the barriers that currently separate experimental efficacy from clinically meaningful CKD outcomes.
F. De Luca, Dario Troise, Valentina Camporeale et al.· Antioxidants· 1 citation
Diabetic kidney disease (DKD) remains the leading cause of chronic kidney disease and end-stage renal failure worldwide despite significant advances in glucose-lowering and renoprotective therapies. Emerging evidence identifies mitochondrial dysfunction as a central pathogenic mechanism linking metabolic stress to chro...
Aasthika Das, Eric Lalu, Vikky Awasthi et al.· Cells· 0 citations
BACKGROUND. Vascular and cardiac calcification is an important contributor to cardiovascular complications in patients with chronic kidney disease (CKD) and is associated with oxidative stress and persistent low-grade inflammation. However, the interactions between these processes and their contribution to cardiovascul...
F. Dzgoeva, I. В. Tedety, O. Remizov et al.· Nephrology (Saint-Petersburg...· 0 citations
This study is the first to illustrate the role and relationship of mitochondrial dysfunction, especially mitophagy, and ferroptosis in renal fibrosis and their interaction with Mfn2, providing new insights and potential therapeutic targets for renal fibrosis.
Mingyu Zhang, Jingyu Wang, Ying Yang et al.· Biochimica et Biophysica Act...· 0 citations
Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...
Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al.· Nature Reviews Nephrology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.